Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A Multicenter, Open Label Study of Promitil for the Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After First Line Therapy

NCT06478862 is registered in ClinicalTrials.gov with Lipomedix Pharmaceuticals Inc. as lead sponsor.

NCT NCT06478862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06478862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A Multicenter, Open Label Study of Promitil for the Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After First Line Therapy
Lead sponsor
Lipomedix Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Terminated
Start date
June 13, 2024
Completion date
January 2, 2026
Enrollment
19 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of ovary, pancreatic ductal adenocarcinoma